MAGeCK and EdgeR analyses of guide abundance revealed that almost all PD-L1 sgRNAs were depleted in tumors from WT mice compared to T cell-depleted mice, but enriched in immunotherapy tumors compared to WT tumors (Fig. 2c; Supplementary Data 1), consistent with the inhibitory function of PD-L1 in cancer cells to induce exhaustion of PD-1-expressing T cells38. This evidence concerns the gene PDCD1 and cancer.